Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Restructuring Costs (2021 - 2023)

Theravance Biopharma (TBPH) has disclosed Restructuring Costs for 3 consecutive years, with $1.2 million as the latest value for Q2 2023.

  • On a quarterly basis, Restructuring Costs fell 61.1% to $1.2 million in Q2 2023 year-over-year; TTM through Sep 2023 was $2.7 million, a 95.48% decrease, with the full-year FY2023 number at $2.7 million, down 78.57% from a year prior.
  • Restructuring Costs was $1.2 million for Q2 2023 at Theravance Biopharma, down from $1.6 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $33.0 million in Q3 2022 to a low of $1.2 million in Q2 2023.
  • A 3-year average of $10.6 million and a median of $6.2 million in 2022 define the central range for Restructuring Costs.
  • Peak YoY movement for Restructuring Costs: skyrocketed 114.29% in 2022, then tumbled 83.08% in 2023.
  • Theravance Biopharma's Restructuring Costs stood at $15.4 million in 2021, then surged by 114.29% to $33.0 million in 2022, then plummeted by 96.46% to $1.2 million in 2023.
  • Per Business Quant, the three most recent readings for TBPH's Restructuring Costs are $1.2 million (Q2 2023), $1.6 million (Q1 2023), and $33.0 million (Q3 2022).